Paper published in a journal (Scientific congresses and symposiums)
Phase III study of Ribociclib (LEE011) in combination with Fulvestrant for the treatment of postmenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) who have received no or only one line of prior endocrine treatment : MONALEESA-3
JERUSALEM, Guy ; Centre Hospitalier Universitaire de Liège - CHU > Service d'oncologie médicale
Pivot, X.
Martin, M.
De Laurentiis, M.
Blackwell, K.
Esteva, F.J.
Paquet-Luzy, T.
Tang, Z.
Lorenc, K.R.
Slamon, D.J.
Language :
English
Title :
Phase III study of Ribociclib (LEE011) in combination with Fulvestrant for the treatment of postmenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) who have received no or only one line of prior endocrine treatment : MONALEESA-3
Publication date :
2016
Event name :
38th Annual SABCS
Event place :
San Antonio, United States
Event date :
December 8-12, 2015
Audience :
International
Journal title :
Clinical Cancer Research
ISSN :
1078-0432
eISSN :
1557-3265
Publisher :
American Association for Cancer Research, Philadeplphia, United States - Pennsylvania
